Company: CI
Filing Date: 2025-03-14
Form Type: DEF 14A
Source: 0001739940-25-000015
Chunk: 4

Company: Cigna Group
Filing Date: 2025-03-14
Form: DEF 14A
Chunk 4
---
 |     |                                                                                                                                                                                                                           |     |                                                                                                                                                      |     |                                                    |
|                     |     |                                                                                                                                                                                                                                                                    |     | At the meeting.To vote during the Annual Meeting, visit www.virtualshareholdermeeting.com/CI2025 and enter the 16-digit control number included in your notice of internet availability of proxy materials or proxy card. |     |                                                                                                                                                      |     |                                                    |

| Voting Recommendation |     |                                                                                                                                             |     |                                          |     |      |
| Items of Business     |     |                                                                                                                                             |     | Board                                    
 Recommendation                           |     | Page |
| 1                     |     | Election of eleven director nominees named in this Proxy Statement for one-year terms to expire at the next Annual Meeting of shareholders. |     | FORthe election of each director nominee |     |   12 |
| 2                     |     | Advisory approval of executive compensation.                                                                                                |     | FOR                                      |     |   51 |
| 3                     |     | Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for 2025.      |     | FOR                                      |     |  102 |
| 4                     |     | Shareholder Proposal – Support special shareholder meeting improvement, if properly presented.                                              |     | AGAINST                                  |     |  106 |

| The Cigna Group| 2025 Notice of Annual Meeting of Shareholders and Proxy Statement |     | 1 |

| PROXY STATEMENT SUMMARY |

#### 2024 Performance and Accomplishments
Delivering in a Dynamic Environment

Thanks to the dedicated efforts of our approximately 70,000 colleagues around the world, The Cigna Group delivered the following financial results for fiscal year 2024:

• Grew full-year total revenue by 27% to $247.1 billion.

• Achieved full-year shareholders’ net income per share of $12.12 and adjusted income from operations, per share* of $27.33.

• Returned $8.6 billion to shareholders through share repurchases and dividends.

To drive meaningful value for all our stakeholders, we announced the sale of our Medicare businesses to Health Care Service Corporation (HCSC). The transaction is expected to close in the first quarter of 2025, subject to receipt of applicable regulatory approvals and other customary closing conditions.

Continuing to Drive Our Growth Strategy

We innovated, partnered, expanded access to care, and delivered differentiated value to improve lives and advance our vision for the future of